HRAS and salivary gland carcinoma: The fact that HRAS mutations are more prevalent in salivary gland carcinomas compared to HNSCCs, and are likely associated with poorer prognosis, suggests that HRAS-targeted therapy such as tipifarnib may hold significant promise not only for HNSCCs but also for salivary gland carcinomas.